MARKET WIREChartMill • 3d ago
Gap-Up and Gap-Down Stocks in the Oct. 29, 2026 SessionOct. 29, 2026 gap movers include NCPL, PCLA, INLF, ADT, GKOS, PRCH, CROX, CLMB, TDOC and KFIIR on the upside, plus GME.W, OPTT, LVWR and XRX on the downside.
Why CHRS Stock dropped -22.55% Today — RQD Quant Desk Flash
$0.90 -22.55% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.86
Coherus Oncology Inc. (CHRS) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $138.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on CHRS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CHRS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Coherus Oncology Inc. (NASDAQ: CHRS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $0.90 (-22.55% 1D, market cap $138.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CHRS ranks #642 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CHRS compare to CRDL and CMPX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CHRS carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CRDL (Cardiol Therapeutics Inc. (Class A)) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $141.2M) and CMPX (Compass Therapeutics Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -34.6%, cap $136.2M). Among the 5-stock peer group, CHRS leads on earnings multiple (N/A) while CMPX leads on capital efficiency (-34.6% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CHRS?
▼
Per CHRS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001512762), Coherus Oncology Inc. generated $0 in revenue, $168.0M in net income, and -$138.5M in free cash flow against $258.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.86 (-4.25%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-10% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CHRS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY CHRS SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (28% of score)
FRED Regime × Technicals: 5% of 52W Range • RSI-14 at 34.3 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)
Capital intensity & 0% operating margin leave 16 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$1.07-7.5% Next Q
44
Q2 (-2Q)Grade D$0.99+2% Next Q
41
Q3 (-1Q)Grade E$1.01-10.9% Next Q
39
CurrentGrade D-$0.90-8.3% Hist 90D α
36
Trajectory: D (44) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a CHRS Turnaround Squeeze
While CHRS currently carries a cautious 36/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.20) and Max Pain ($0.95) forces dealer call-delta covering toward $2.75.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CHRS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CHRS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CHRS Stock dropped -22.55% Today — RQD Quant Desk Flash
Coherus Oncology Inc. (CHRS) dropped -22.55% to $0.90, trading at 5% of its 52-week range ($0.81 – $2.62). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 5% of its 52-week range ($0.81 – $2.62) with RSI-14 at 34.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.90 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live CHRS Headlines & Catalysts
MARKET WIREBenzinga • 3d ago
12 Health Care Stocks Moving In Thursday's Intraday SessionGainers Glaukos (NYSE:GKOS) shares rose 30.8% to $237.26 during Thursday's regular session. The company's market cap stands at $10.7 billion. The company's, Q3 earnings came out yesterday. Teladoc Health
MARKET WIREBenzinga • 4d ago
HC Wainwright & Co. Assumes Coherus Oncology at Buy, Announces Price Target of $7HC Wainwright & Co. analyst Swayampakula Ramakanth assumes Coherus Oncology (NASDAQ:CHRS) with a Buy rating and announces Price Target of $7.
MARKET WIREBenzinga • 4d ago
12 Health Care Stocks Moving In Thursday's Pre-Market SessionGainers Mesoblast (NASDAQ:MESO) stock rose 16.2% to $15.57 during Thursday's pre-market session. The market value of their outstanding shares is at $1.7 billion. Glaukos (NYSE:GKOS) stock rose 15.75% to $210.01.
MARKET WIRESeekingAlpha • 4d ago
Coherus Oncology, Inc. (CHRS) Discusses Tagmokitug Interim Clinical Data in Esophageal Cancer TranscriptCoherus Oncology, Inc. (CHRS) Discusses Tagmokitug Interim Clinical Data in Esophageal Cancer October 28, 2026 4:30 PM EDTCompany ParticipantsCarrie Graham...
RISK WATCHYahoo • 4d ago
Coherus Oncology Reports 89% Response Rate in Early ESCC StudyCoherus Oncology (NASDAQ:CHRS) presented interim clinical data for tagmokitug, an investigational therapy designed to target CCR8-positive regulatory T cells, in several solid-tumor settings. The company highlighted earl
MARKET WIREYahoo • 4d ago
Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development-1L ESCC confirmed ORR of 75% irrespective of PD-L1 status, confirmed ORR of 100% for PD-L1- positive, in evaluable patients- -2L ESCC durable clinical benefit observed with a clear dose-response irrespective of PD-L1 st
MARKET WIREYahoo • 5d ago
Coherus to Participate in Upcoming Investor ConferencesREDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be webcasting its participation in the following upcoming investor conferences: Guggenh
MARKET WIREYahoo • 6d ago
Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026REDWOOD CITY, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its third quarter 2026 financial results will be released on Monday, November 9, 2026. Starting at 5:00
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CHRS)
- ✓Walkthrough of CHRS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CHRS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -49.15%🛡️ HOLDING TREND SUPPORT
2026-10-30O $0.90H $0.92L $0.82C $0.90VOL 2.19M
RES: $1.28SUP: $0.81SMA50: $1.20SMA200: $1.53
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CHRS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CHRS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CHRS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CHRS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CHRS)
Health Care Rank #642 of 1016
⚔️ CRDL vs CHRS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CHRS vs. CRDL, CMPX, MOLN, HUMA)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Coherus Oncology Inc. (CHRS) ranks #642 by composite RQD confidence (36/100, grade D-) and #619 by equity capitalization ($138.8M). Within this direct 5-issuer industry benchmark cohort, CHRS leads on earnings valuation at N/A trailing P/E, while CMPX leads on capital efficiency and profitability with -34.6% ROIC and — gross margin. CRDL currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with CHRS at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CHRS
ACTIVE
Coherus Oncology Inc. | D- | 36/100 | — | — | -35.0% | -22.55% | $138.8M | Benchmark Subject |
| CRDL Cardiol Therapeutics Inc. (Class A) | D+ | 52/100 | — | — | — | 0.00% | $141.2M | /crdl-vs-chrs → |
| CMPX Compass Therapeutics Inc. | D | 46/100 | — | — | -34.6% | -0.54% | $136.2M | /cmpx-vs-chrs → |
| MOLN Molecular Partners AG | D | 50/100 | — | — | — | -4.88% | $132.4M | /moln-vs-chrs → |
| HUMA Humacyte Inc. | E | 31/100 | — | -30.0% | -35.0% | -0.06% | $130.5M | /huma-vs-chrs → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001512762In its most recent audited fiscal period (FY2025, filed 2025-12-31), Coherus Oncology Inc. (CHRS) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $168.0M, operating cash flow of -$138.5M, and free cash flow of -$138.5M (-577.7% YoY). On the balance sheet, CHRS closed FY2025 with $258.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $168.0M | -$138.5M | -$138.5M | $258.3M | — |
| FY2024 (FY) | 2024-12-31 | $0 | $28.5M | -$20.4M | -$20.4M | $448.5M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$237.9M | -$174.9M | -$174.9M | — | — |
3. CHRS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CHRS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Coherus Oncology Inc. (NASDAQ: CHRS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $0.90 (-22.55% 1D, market cap $138.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CHRS ranks #642 in composite RQD confidence.
How does CHRS compare to CRDL and CMPX in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CHRS carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CRDL (Cardiol Therapeutics Inc. (Class A)) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $141.2M) and CMPX (Compass Therapeutics Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -34.6%, cap $136.2M). Among the 5-stock peer group, CHRS leads on earnings multiple (N/A) while CMPX leads on capital efficiency (-34.6% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CHRS?
Per CHRS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001512762), Coherus Oncology Inc. generated $0 in revenue, $168.0M in net income, and -$138.5M in free cash flow against $258.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CHRS trading relative to its 50-day, 200-day, and 52-week technical levels?
CHRS last traded at $0.90 (-22.55% on volume of 6,138,709 shares), positioning the stock -25.00% below its 50-day simple moving average ($1.20) and -41.18% below its 200-day simple moving average ($1.53). Across its 52-week range of $0.81 to $2.62, CHRS sits at the 5.0% percentile with a 14-day RSI of 34.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.01).
CHRS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CHRS stock moving today?
Why CHRS Stock dropped -22.55% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.